An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.

Inclusion Criteria: * Body mass index (BMI) from 18 - 25; body weight ≥50kg. * Diagnosis of HIV infections/AIDS based on "Diagnostic Criteria for HIV/AIDS" WS 293-2008. * No antiretroviral therapy (ART) in the past 6 weeks and refuse to receive ART. * CD4 T cell count ≥350/μl. * No plan for pregnancy in the near future and agree to practice non-drug based contraception. * Voluntary to participate in the study, comply with the study design to complete all monitory measurements, and agree to sign the study agreement. Exclusion Criteria: * Existence of infections/opportunistic tumors. * Mutations in the shRNA target sequences. * White blood cell count \<3x10\^9/L, neutrophil count \<1.5x10\^9/L, hemoglobin \<110g/L, platelet count \<100x10\^9/L. * Liver diseases (HBV, chronic HCV infection, congenital liver metabolic disease), abnormal liver functions (test value 2x above normal). * Kidney deficiency (Creatinine level above the upper limit of normal levels). * Severe chronic disease, metabolic disease (e.g., diabetes), neurological and psychiatric diseases. * History of pancreatitis. * Women in pregnancy, lactating or at reproductive age who do not practice contraception. * Allergy to agents or drugs used in the study. * Verified or suspected abuse of alcohol and drugs. * Participated in other clinical trials within 3 months. * Based on investigator's assessment, those who are unfit for the study (e.g., general weakness, poor compliance with study design). * Personal or family history of tumors.